Compare Quanta Services Inc (PWR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Viatris Inc — how do they compare? Quanta Services Inc trades at $643.13 (market cap $95.92B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Quanta Services Inc is far larger — about 4.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| PWR | VTRS | |
|---|---|---|
Market Cap | $95.92B | $20.50B |
Sector | Industrials | Health |
52-Week High | $785.24 | $17.59 |
52-Week Low | $372.50 | $8.74 |
Enterprise Value | $101.87B | $32.71B |
Dividend Yield | 0.07% | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
